European Primary Care Cardiovascular Society

Heart Failure

Follow the news, literature, and elearning on new developments in the management of Heart Failure.

New diagnostic strategy to improve early CVD diagnosis in primary care patients with COPD or T2D

3' education - Oct. 11, 2023 - Amy Groenewegen, MD

Unique randomized withdrawal heart failure trial with SGLT2i

3' education - Oct. 9, 2023 - Milton Packer, MD

Clinically meaningful benefits with GLP-1RA in patients with HFpEF and obesity

3' education - Oct. 9, 2023 - Mikhail Kosiborod, MD

Benefits of rapid uptitration of HF medications independent of baseline renal function

3' education - July 13, 2023 - Jozine ter Maaten, MD, PhD

ARNI superior to ARB in reducing NT-proBNP in patients with HFmrEF/HFpEF

3' education - July 13, 2023 - Robert Mentz, MD

Remote hemodynamic monitoring improves quality of life and reduces HF hospitalizations in HF

3' education - July 13, 2023 - Jasper Brugts, MD, PhD

No association of early eGFR decline after transitioning to ARNI with adverse outcomes

3' education - Mar. 14, 2023 - Safia Chatur, MD

Improved outcomes with SGLT2i in HFpEF and HFmrEF

3' education - Aug. 27, 2022 - Prof. Scott Solomon, MD

Patients with heart failure benefit from SGLT2i regardless of ejection fraction

3' education - Aug. 27, 2022 - Prof. Pardeep Jhund, MD, PhD

Potassium binder results in optimization of RAASi and low risk of hyperkalemia in HFrEF

3' education - Apr. 14, 2022 - Prof. Javed Butler, MD

Quality of care improved with EHR-based intervention for patients with HF

3' education - Apr. 13, 2022 - Tariq Ahmad, MD

Clinical events with low-sodium diet in HF

3' education - Apr. 12, 2022 - Prof. Justin Ezekowitz

Are HF patients harmed when they add salt to their egg?

3' education - Apr. 3, 2022 - Joseph Cleveland, MD

Iron deficiency in HF: Outcomes, pathophysiology and management

10' education - Mar. 7, 2022 - Robert Mentz, MD and prof. Peter van der Meer, MD, PhD

Evaluating the role of a non-steroidal MRA in patients with T2DM and CKD

10' education - Feb. 8, 2022 - Prof. Peter Rossing, MD, prof. Gerasimos Filippatos, MD and prof. Matthew Weir, MD

A pooled analysis of two large HF trials with SGLT2i shows exciting findings

3' education - Oct. 5, 2021 - Milton Packer, MD

The 2021 ESC HF guidelines: What is new regarding patients with EF>40%?

3' education - Sep. 10, 2021 - Prof. Carolyn Lam, MD, PhD

Proven safety with ARNI in MI patients, but no definite difference for primary endpoint

5' education - May 27, 2021 - Prof. Marc Pfeffer, MD, PhD

The therapeutic options in HFrEF patients

3' education - Dec. 3, 2020 - Prof. Marc Pfeffer, MD, PhD

Reduced HF hospitalization in patients with iron deficiency after acute HF treated with ferric carboxymaltose

5' education - Dec. 3, 2020 - Prof. Piotr Ponikowski, MD, PhD

All three end points show benefit with another SLGT2 inhibitor in HFrEF

3' education - Sep. 16, 2020 - Milton Packer, MD

Screening for AF, HF and CAD in primary care

5' education - June 16, 2020 - Victor Zwartkruis

sGC stimulator has added value in worsening HFrEF patients

3' education - Apr. 10, 2020 - Prof. Paul Armstrong, MD - ACC 2020

ARNI seems to give CV benefit up to EF of about 60%, not only in HFrEF

3' education - Nov. 16, 2019 - Scott Solomon, Boston - AHA 2019, Philadelphia

Does HF have two physiologies that respond differently to treatment, or is it the same disease across the EF spectrum?

3' education - Nov. 18, 2019 - Lynne Stevenson, Nashville - AHA 2019, Philadelphia

SGLT2 inhibitor improves health status in HFrEF

3' education - Nov. 17, 2019 - Mikhail Kosiborod, Kansas City - AHA 2019, Philadelphia
EPCCS Annual CV Summit

Heart failure and comorbidities: kidney disease and cancer

5' education - Mar. 22, 2019 - Lisbon, Portugal - Peter van der Meer & Monika Hollander

SGLT2 inhibitor greatly reduced CV risk in HFrEF with or without diabetes

3' education - Sep. 16, 2019 - Paris, France - Prof. John McMurray
EPCCS Annual CV Summit

New diagnostic algorithm and therapeutic options in HF management

5' education - Mar. 22, 2019 - Lisbon, Portugal - Peter van der Meer & Monika Hollander

EPCCS

3' education - Feb. 8, 2019

Treatment effect of SGLT2i across background of glucose-lowering therapies in T2D and HFmrEF/HFpEF

News - Oct. 11, 2023

EASD 2023 In patients with T2D and HFmrEF/HFpEF, the treatment effect of dapagliflozin on the primary outcome was consistent across the number and most types of baseline glucose-lowering therapies.

New diagnostic strategy to improve early CVD diagnosis in primary care patients with COPD or T2D

3' education - Oct. 11, 2023 - Amy Groenewegen, MD
**ESC Congress 2023** In the RED-CVD study, it was investigated whether a new diagnostic strategy could increase the number of new CVD diagnoses in primary care patients with COPD or T2D compared with usual care. Amy Groenewegen shares the results.

ESC Congress 2023 In the RED-CVD study, it was investigated whether a new diagnostic strategy could increase the number of new CVD diagnoses in primary care patients with COPD or T2D compared with usual care. Amy Groenewegen shares the results.

Unique randomized withdrawal heart failure trial with SGLT2i

3' education - Oct. 9, 2023 - Milton Packer, MD
**ESC Congress 2023** After initiation of drugs, patients are on medications for years. But do the drugs still work? Milton Packer shares the outcomes of a randomized withdrawal trial with empagliflozin in patients with HF.

ESC Congress 2023 After initiation of drugs, patients are on medications for years. But do the drugs still work? Milton Packer shares the outcomes of a randomized withdrawal trial with empagliflozin in patients with HF.

Clinically meaningful benefits with GLP-1RA in patients with HFpEF and obesity

3' education - Oct. 9, 2023 - Mikhail Kosiborod, MD
**ESC Congress 2023 ** The STEP-HFpEF trial shows that semaglutide improves HF-related symptoms and leads to greater weight loss in patients with HFpEF. “Collectively, these findings indicate that semaglutide is a valuable treatment option in patients with HFpEF and obesity” says Mikhail Kosiborod.

ESC Congress 2023 The STEP HFpEF trial shows that semaglutide improves HF-related symptoms and leads to greater weight loss in patients with HFpEF. “Collectively, these findings indicate that semaglutide is a valuable treatment option in patients with HFpEF and obesity” says Mikhail Kosiborod.

Increased risk of CV death, HF and AF in breast cancer survivors

Literature - Oct. 5, 2023 - Galimzhanov A, et al. - Eur J Prev Cardiol. 2023

A meta-analysis showed that breast cancer survivors have an increased risk of CV death, HF, and AF, but not of CAD, MI, or ischemic stroke, compared with the general population.

Global association of the PURE healthy diet score with health outcomes

Literature - Sep. 25, 2023 - Mente A et al. - Eur Heart J. 2023

Using data of persons from 80 countries, it was demonstrated that a diet with higher amounts of fruit, vegetables, legumes, nuts, and a moderate amount of fish and (whole-fat) diary was associated with lower risk of CVD and mortality globally, especially in low-income countries.

Consistent benefit of SGLT2 inhibitors on CV outcomes across various patient populations

Literature - Sep. 21, 2023 - Usman MS, et al. - J Am Coll Cardiol. 2023

What are the effects of SGLT2 inhibitors on CV outcomes across different subgroups of patients? This was investigated in a meta-analysis of 13 RCTs in patients with HF, T2D or CKD, and in patients with varying combinations of these diseases.

Ferric carboxymaltose reduces hospitalization risk in HF patients with iron deficiency

News - Sep. 12, 2023

ESC Congress 2023 In a large pooled analysis, intravenous ferric carboxymaltose reduced the risk of CV hospitalizations or CV death combined, but not mortality alone, in patients with HFrEF/HFmrEF and iron deficiency.

Phase 3 trial with ferric carboxymaltose in HFrEF does not meet hierarchical primary endpoint

News - Sep. 12, 2023

ESC Congress 2023 In HFrEF patients with iron deficiency, IV ferric carboxymaltose resulted in a modest albeit not statistically significant improvement in the hierarchical composite outcome of all-cause mortality, HF hospitalization, and change in exercise capacity.

GLP-1RA improves HF symptoms and physical function in patients with HFpEF and obesity

News - Sep. 12, 2023

ESC Congress 2023 STEP HFpEF showed that once-weekly semaglutide 2.4 mg improved HF-related symptoms, physical limitations and exercise function, and led to greater weight loss in patients with HFpEF and obesity, compared with placebo.

2023 Focused Update of ESC HF guidelines entails new recommendations in three sections

News - Sep. 12, 2023
Well before the next scheduled full ESC guideline on HF, new evidence of several RCTs that should change the management of patients with HF has become available. Therefore, the 2023 Focused Update was presented and published.

ESC Congress 2023 Well before the next scheduled full ESC guideline on HF, new evidence of several RCTs that should change the management of patients with HF has become available. Therefore, the 2023 Focused Update was presented and published.

Improvement of early diagnosis of CVD in primary care patients with COPD or T2D

News - Sep. 4, 2023

ESC Congress 2023 In the RED-CVD trial, it was shown that a proactive diagnostic intervention strategy improves early diagnosis of CVD in primary care patients with COPD and/or T2D.